Is this your brand? Sign in to claim ownership.

Sign in to claim this brand

Instrumentation Laboratory SpA

Italy·IT-MF-000009277

Last updated September 17, 2026

Information

Country
Italy
Address
338, Viale Monza, Milan, Italy
Website
werfen.com/it
Facebook
—
Phone
02 25221
PRRC Contact
Natale Bova
EUDAMED SRN
IT-MF-000009277
FDA FEI Number
3012348571
DUNS Number
—

Catalogue (107)

Page 2 of 3
DeviceModel / ReferenceRegistriesClassStatus
DRI Barbiturate W150224
EUDAMED
Class BActive
ILab Aries w/o ISE 000160258302
EUDAMED
Class AActive
Drying Pad W23010192000
EUDAMED
Class AActive
CEDIA reagent bottle adapter (10 pcs) 0018476300
EUDAMED
Class AActive
DRI Benzodiazepine W150039
EUDAMED
Class BActive
Cuvette Cleaning 0018469600
EUDAMED
Class AActive
DRI Ecstasy W15100075
EUDAMED
Class BActive
10 mL bottle adapter (10 pcs) 0014557200
EUDAMED
Class AActive
False Bottom Tubes (100 pcs) 0018476600
EUDAMED
Class AActive
ReferrIL Urine Albumin 0018169800
EUDAMED
Class BActive
Urine Albumin 0018167840
EUDAMED
Class BActive
Acid Cuvette Cleaner 0018468000
EUDAMED
Class AActive
DRI Ethyl Alcohol W150037
EUDAMED
Class BActive
DRI Amphetamines W150017
EUDAMED
Class BActive
Alkaline Detergent 0018253710
EUDAMED
Class AActive
ILab Aries with ISE 000160258304
EUDAMED
Class AActive
ISE Cleaner 0018165600
EUDAMED
Class AActive
Reagent Bottle 50 mL 0018475900
EUDAMED
Class AActive
Probe Rinse 0018469500
EUDAMED
Class AActive
ILab Taurus Drying Pad 0018470810
EUDAMED
Class AActive
ReferrIL G 0018257000
EUDAMED
Class CActive
10/20 mL bottle adapter W23010262400
EUDAMED
Class AActive
Glucose (Oxidase) 0018250840
EUDAMED
Class CActive
Creatinine Enzymatic 0018259440
EUDAMED
Class BActive
ISE Cleaning 0018482900
EUDAMED
Class AActive
Reagent Bottle 25 mL 0018475800
EUDAMED
Class AActive
20 mL bottle adapter inner ring (10 pcs) 0018461100
EUDAMED
Class AActive
Urine DoA Beta Controls 0018168700
EUDAMED
Class BActive
ISE Diluent 0018253400
EUDAMED
Class AActive
Serachem HbA1c 0018167500
EUDAMED
Class CActive
Total Bilirubin 0018258340
EUDAMED
Class CActive
Urine DoA Zeta Controls 0018168800
EUDAMED
Class BActive
C3 0018169640
EUDAMED
Class BActive
ILab Aries Sample Rack (1 pcs) W230503620
EUDAMED
Class AActive
Reaction Cuvettes W23C1010207700
EUDAMED
Class AActive
ReferrIL HbA1c 0018167400
EUDAMED
Class CActive
Distilled Water Additive 0018468100
EUDAMED
Class AActive
Total Bilirubin 0018254640
EUDAMED
Class CActive
Electrode K 0018263500
EUDAMED
Class BActive
Lithium 0018169040
EUDAMED
Class CActive
Ck-Mb 0018482200
EUDAMED
Class CActive
DRI Ethyl Glucuronide W1510011723
EUDAMED
Class BActive
ILab Taurus refurbished w/o ISE 230V 00001070301R
EUDAMED
Class AActive
ISE Conditioner 0018165800
EUDAMED
Class AActive
DRI Cocaine Metabolite W150055
EUDAMED
Class BActive
ILab Taurus Touch Screen Option Kit 0001156008
EUDAMED
Class AActive
DRI Cannabinoid W150185
EUDAMED
Class BActive
Reagent Bottle 20 mL 0018262902
EUDAMED
Class AActive
ILab Taurus without ISE 120V 00001070303
EUDAMED
Class AActive
Urine Diluent 0018165500
EUDAMED
Class AActive

Related Companies

Authorised Representatives

No authorised representatives on record.

Importers

Not available yet.

Notified Bodies

Not available yet.

Authorities

Not available yet.

FDA Recalls (96)

Recalls reported by this firm to the FDA. Listed at company level — FDA recall records don't identify a specific catalogue device.

DateRecall No.ClassStatusReason
Jan 20, 2026Z-1542-2026—open, classified

Confirmed customer complaints indicating that GEM PAKs (cartridges) for the GEM Premier 5000 may experience an increased incidence of Process Control Solution Not Detected (PCSND) errors during warm-up, including consecutive occurrences, resulting in GEM PAK ejection and requiring insertion of a new GEM PAK. iQM2 is an active quality process control program designed to provide continuous monitoring of the entire testing process. Thus, if a GEM PAK completes AutoPAK Validation following warm-up, it may remain in use. Consecutive GEM PAK ejections during warm-up may prolong turnaround times, potentially delaying results. In such cases, patient management may require reassessment once results are available. While many GEM PAKs continue to perform as intended, consecutive ejections may increase the likelihood of operational disruption, highlighting the importance of advance planning where feasible to help minimize impact.

Jan 20, 2026Z-1532-2026—open, classified

Confirmed customer complaints indicating that GEM PAKs (cartridges) for the GEM Premier 5000 may experience an increased incidence of Process Control Solution Not Detected (PCSND) errors during warm-up, including consecutive occurrences, resulting in GEM PAK ejection and requiring insertion of a new GEM PAK. iQM2 is an active quality process control program designed to provide continuous monitoring of the entire testing process. Thus, if a GEM PAK completes AutoPAK Validation following warm-up, it may remain in use. Consecutive GEM PAK ejections during warm-up may prolong turnaround times, potentially delaying results. In such cases, patient management may require reassessment once results are available. While many GEM PAKs continue to perform as intended, consecutive ejections may increase the likelihood of operational disruption, highlighting the importance of advance planning where feasible to help minimize impact.

Jan 20, 2026Z-1536-2026—open, classified

Confirmed customer complaints indicating that GEM PAKs (cartridges) for the GEM Premier 5000 may experience an increased incidence of Process Control Solution Not Detected (PCSND) errors during warm-up, including consecutive occurrences, resulting in GEM PAK ejection and requiring insertion of a new GEM PAK. iQM2 is an active quality process control program designed to provide continuous monitoring of the entire testing process. Thus, if a GEM PAK completes AutoPAK Validation following warm-up, it may remain in use. Consecutive GEM PAK ejections during warm-up may prolong turnaround times, potentially delaying results. In such cases, patient management may require reassessment once results are available. While many GEM PAKs continue to perform as intended, consecutive ejections may increase the likelihood of operational disruption, highlighting the importance of advance planning where feasible to help minimize impact.

Jan 20, 2026Z-1533-2026—open, classified

Confirmed customer complaints indicating that GEM PAKs (cartridges) for the GEM Premier 5000 may experience an increased incidence of Process Control Solution Not Detected (PCSND) errors during warm-up, including consecutive occurrences, resulting in GEM PAK ejection and requiring insertion of a new GEM PAK. iQM2 is an active quality process control program designed to provide continuous monitoring of the entire testing process. Thus, if a GEM PAK completes AutoPAK Validation following warm-up, it may remain in use. Consecutive GEM PAK ejections during warm-up may prolong turnaround times, potentially delaying results. In such cases, patient management may require reassessment once results are available. While many GEM PAKs continue to perform as intended, consecutive ejections may increase the likelihood of operational disruption, highlighting the importance of advance planning where feasible to help minimize impact.

Jan 20, 2026Z-1527-2026—open, classified

Confirmed customer complaints indicating that GEM PAKs (cartridges) for the GEM Premier 5000 may experience an increased incidence of Process Control Solution Not Detected (PCSND) errors during warm-up, including consecutive occurrences, resulting in GEM PAK ejection and requiring insertion of a new GEM PAK. iQM2 is an active quality process control program designed to provide continuous monitoring of the entire testing process. Thus, if a GEM PAK completes AutoPAK Validation following warm-up, it may remain in use. Consecutive GEM PAK ejections during warm-up may prolong turnaround times, potentially delaying results. In such cases, patient management may require reassessment once results are available. While many GEM PAKs continue to perform as intended, consecutive ejections may increase the likelihood of operational disruption, highlighting the importance of advance planning where feasible to help minimize impact.

Jan 20, 2026Z-1531-2026—open, classified

Confirmed customer complaints indicating that GEM PAKs (cartridges) for the GEM Premier 5000 may experience an increased incidence of Process Control Solution Not Detected (PCSND) errors during warm-up, including consecutive occurrences, resulting in GEM PAK ejection and requiring insertion of a new GEM PAK. iQM2 is an active quality process control program designed to provide continuous monitoring of the entire testing process. Thus, if a GEM PAK completes AutoPAK Validation following warm-up, it may remain in use. Consecutive GEM PAK ejections during warm-up may prolong turnaround times, potentially delaying results. In such cases, patient management may require reassessment once results are available. While many GEM PAKs continue to perform as intended, consecutive ejections may increase the likelihood of operational disruption, highlighting the importance of advance planning where feasible to help minimize impact.

Jan 20, 2026Z-1529-2026—open, classified

Confirmed customer complaints indicating that GEM PAKs (cartridges) for the GEM Premier 5000 may experience an increased incidence of Process Control Solution Not Detected (PCSND) errors during warm-up, including consecutive occurrences, resulting in GEM PAK ejection and requiring insertion of a new GEM PAK. iQM2 is an active quality process control program designed to provide continuous monitoring of the entire testing process. Thus, if a GEM PAK completes AutoPAK Validation following warm-up, it may remain in use. Consecutive GEM PAK ejections during warm-up may prolong turnaround times, potentially delaying results. In such cases, patient management may require reassessment once results are available. While many GEM PAKs continue to perform as intended, consecutive ejections may increase the likelihood of operational disruption, highlighting the importance of advance planning where feasible to help minimize impact.

Jan 20, 2026Z-1535-2026—open, classified

Confirmed customer complaints indicating that GEM PAKs (cartridges) for the GEM Premier 5000 may experience an increased incidence of Process Control Solution Not Detected (PCSND) errors during warm-up, including consecutive occurrences, resulting in GEM PAK ejection and requiring insertion of a new GEM PAK. iQM2 is an active quality process control program designed to provide continuous monitoring of the entire testing process. Thus, if a GEM PAK completes AutoPAK Validation following warm-up, it may remain in use. Consecutive GEM PAK ejections during warm-up may prolong turnaround times, potentially delaying results. In such cases, patient management may require reassessment once results are available. While many GEM PAKs continue to perform as intended, consecutive ejections may increase the likelihood of operational disruption, highlighting the importance of advance planning where feasible to help minimize impact.

Jan 20, 2026Z-1538-2026—open, classified

Confirmed customer complaints indicating that GEM PAKs (cartridges) for the GEM Premier 5000 may experience an increased incidence of Process Control Solution Not Detected (PCSND) errors during warm-up, including consecutive occurrences, resulting in GEM PAK ejection and requiring insertion of a new GEM PAK. iQM2 is an active quality process control program designed to provide continuous monitoring of the entire testing process. Thus, if a GEM PAK completes AutoPAK Validation following warm-up, it may remain in use. Consecutive GEM PAK ejections during warm-up may prolong turnaround times, potentially delaying results. In such cases, patient management may require reassessment once results are available. While many GEM PAKs continue to perform as intended, consecutive ejections may increase the likelihood of operational disruption, highlighting the importance of advance planning where feasible to help minimize impact.

Jan 20, 2026Z-1524-2026—open, classified

Confirmed customer complaints indicating that GEM PAKs (cartridges) for the GEM Premier 5000 may experience an increased incidence of Process Control Solution Not Detected (PCSND) errors during warm-up, including consecutive occurrences, resulting in GEM PAK ejection and requiring insertion of a new GEM PAK. iQM2 is an active quality process control program designed to provide continuous monitoring of the entire testing process. Thus, if a GEM PAK completes AutoPAK Validation following warm-up, it may remain in use. Consecutive GEM PAK ejections during warm-up may prolong turnaround times, potentially delaying results. In such cases, patient management may require reassessment once results are available. While many GEM PAKs continue to perform as intended, consecutive ejections may increase the likelihood of operational disruption, highlighting the importance of advance planning where feasible to help minimize impact.

Jan 20, 2026Z-1525-2026—open, classified

Confirmed customer complaints indicating that GEM PAKs (cartridges) for the GEM Premier 5000 may experience an increased incidence of Process Control Solution Not Detected (PCSND) errors during warm-up, including consecutive occurrences, resulting in GEM PAK ejection and requiring insertion of a new GEM PAK. iQM2 is an active quality process control program designed to provide continuous monitoring of the entire testing process. Thus, if a GEM PAK completes AutoPAK Validation following warm-up, it may remain in use. Consecutive GEM PAK ejections during warm-up may prolong turnaround times, potentially delaying results. In such cases, patient management may require reassessment once results are available. While many GEM PAKs continue to perform as intended, consecutive ejections may increase the likelihood of operational disruption, highlighting the importance of advance planning where feasible to help minimize impact.

Jan 20, 2026Z-1541-2026—open, classified

Confirmed customer complaints indicating that GEM PAKs (cartridges) for the GEM Premier 5000 may experience an increased incidence of Process Control Solution Not Detected (PCSND) errors during warm-up, including consecutive occurrences, resulting in GEM PAK ejection and requiring insertion of a new GEM PAK. iQM2 is an active quality process control program designed to provide continuous monitoring of the entire testing process. Thus, if a GEM PAK completes AutoPAK Validation following warm-up, it may remain in use. Consecutive GEM PAK ejections during warm-up may prolong turnaround times, potentially delaying results. In such cases, patient management may require reassessment once results are available. While many GEM PAKs continue to perform as intended, consecutive ejections may increase the likelihood of operational disruption, highlighting the importance of advance planning where feasible to help minimize impact.

Jan 20, 2026Z-1528-2026—open, classified

Confirmed customer complaints indicating that GEM PAKs (cartridges) for the GEM Premier 5000 may experience an increased incidence of Process Control Solution Not Detected (PCSND) errors during warm-up, including consecutive occurrences, resulting in GEM PAK ejection and requiring insertion of a new GEM PAK. iQM2 is an active quality process control program designed to provide continuous monitoring of the entire testing process. Thus, if a GEM PAK completes AutoPAK Validation following warm-up, it may remain in use. Consecutive GEM PAK ejections during warm-up may prolong turnaround times, potentially delaying results. In such cases, patient management may require reassessment once results are available. While many GEM PAKs continue to perform as intended, consecutive ejections may increase the likelihood of operational disruption, highlighting the importance of advance planning where feasible to help minimize impact.

Jan 20, 2026Z-1537-2026—open, classified

Confirmed customer complaints indicating that GEM PAKs (cartridges) for the GEM Premier 5000 may experience an increased incidence of Process Control Solution Not Detected (PCSND) errors during warm-up, including consecutive occurrences, resulting in GEM PAK ejection and requiring insertion of a new GEM PAK. iQM2 is an active quality process control program designed to provide continuous monitoring of the entire testing process. Thus, if a GEM PAK completes AutoPAK Validation following warm-up, it may remain in use. Consecutive GEM PAK ejections during warm-up may prolong turnaround times, potentially delaying results. In such cases, patient management may require reassessment once results are available. While many GEM PAKs continue to perform as intended, consecutive ejections may increase the likelihood of operational disruption, highlighting the importance of advance planning where feasible to help minimize impact.

Jan 20, 2026Z-1530-2026—open, classified

Confirmed customer complaints indicating that GEM PAKs (cartridges) for the GEM Premier 5000 may experience an increased incidence of Process Control Solution Not Detected (PCSND) errors during warm-up, including consecutive occurrences, resulting in GEM PAK ejection and requiring insertion of a new GEM PAK. iQM2 is an active quality process control program designed to provide continuous monitoring of the entire testing process. Thus, if a GEM PAK completes AutoPAK Validation following warm-up, it may remain in use. Consecutive GEM PAK ejections during warm-up may prolong turnaround times, potentially delaying results. In such cases, patient management may require reassessment once results are available. While many GEM PAKs continue to perform as intended, consecutive ejections may increase the likelihood of operational disruption, highlighting the importance of advance planning where feasible to help minimize impact.

Jan 20, 2026Z-1540-2026—open, classified

Confirmed customer complaints indicating that GEM PAKs (cartridges) for the GEM Premier 5000 may experience an increased incidence of Process Control Solution Not Detected (PCSND) errors during warm-up, including consecutive occurrences, resulting in GEM PAK ejection and requiring insertion of a new GEM PAK. iQM2 is an active quality process control program designed to provide continuous monitoring of the entire testing process. Thus, if a GEM PAK completes AutoPAK Validation following warm-up, it may remain in use. Consecutive GEM PAK ejections during warm-up may prolong turnaround times, potentially delaying results. In such cases, patient management may require reassessment once results are available. While many GEM PAKs continue to perform as intended, consecutive ejections may increase the likelihood of operational disruption, highlighting the importance of advance planning where feasible to help minimize impact.

Jan 20, 2026Z-1539-2026—open, classified

Confirmed customer complaints indicating that GEM PAKs (cartridges) for the GEM Premier 5000 may experience an increased incidence of Process Control Solution Not Detected (PCSND) errors during warm-up, including consecutive occurrences, resulting in GEM PAK ejection and requiring insertion of a new GEM PAK. iQM2 is an active quality process control program designed to provide continuous monitoring of the entire testing process. Thus, if a GEM PAK completes AutoPAK Validation following warm-up, it may remain in use. Consecutive GEM PAK ejections during warm-up may prolong turnaround times, potentially delaying results. In such cases, patient management may require reassessment once results are available. While many GEM PAKs continue to perform as intended, consecutive ejections may increase the likelihood of operational disruption, highlighting the importance of advance planning where feasible to help minimize impact.

Jan 20, 2026Z-1526-2026—open, classified

Confirmed customer complaints indicating that GEM PAKs (cartridges) for the GEM Premier 5000 may experience an increased incidence of Process Control Solution Not Detected (PCSND) errors during warm-up, including consecutive occurrences, resulting in GEM PAK ejection and requiring insertion of a new GEM PAK. iQM2 is an active quality process control program designed to provide continuous monitoring of the entire testing process. Thus, if a GEM PAK completes AutoPAK Validation following warm-up, it may remain in use. Consecutive GEM PAK ejections during warm-up may prolong turnaround times, potentially delaying results. In such cases, patient management may require reassessment once results are available. While many GEM PAKs continue to perform as intended, consecutive ejections may increase the likelihood of operational disruption, highlighting the importance of advance planning where feasible to help minimize impact.

Jan 20, 2026Z-1534-2026—open, classified

Confirmed customer complaints indicating that GEM PAKs (cartridges) for the GEM Premier 5000 may experience an increased incidence of Process Control Solution Not Detected (PCSND) errors during warm-up, including consecutive occurrences, resulting in GEM PAK ejection and requiring insertion of a new GEM PAK. iQM2 is an active quality process control program designed to provide continuous monitoring of the entire testing process. Thus, if a GEM PAK completes AutoPAK Validation following warm-up, it may remain in use. Consecutive GEM PAK ejections during warm-up may prolong turnaround times, potentially delaying results. In such cases, patient management may require reassessment once results are available. While many GEM PAKs continue to perform as intended, consecutive ejections may increase the likelihood of operational disruption, highlighting the importance of advance planning where feasible to help minimize impact.

Jan 20, 2026Z-1543-2026—open, classified

Confirmed customer complaints indicating that GEM PAKs (cartridges) for the GEM Premier 5000 may experience an increased incidence of Process Control Solution Not Detected (PCSND) errors during warm-up, including consecutive occurrences, resulting in GEM PAK ejection and requiring insertion of a new GEM PAK. iQM2 is an active quality process control program designed to provide continuous monitoring of the entire testing process. Thus, if a GEM PAK completes AutoPAK Validation following warm-up, it may remain in use. Consecutive GEM PAK ejections during warm-up may prolong turnaround times, potentially delaying results. In such cases, patient management may require reassessment once results are available. While many GEM PAKs continue to perform as intended, consecutive ejections may increase the likelihood of operational disruption, highlighting the importance of advance planning where feasible to help minimize impact.

Dec 11, 2025Z-1095-2026—open, classified

Potential for microbial contamination.

Nov 18, 2025Z-0938-2026—open, classified

Recalled lots were manufactured with double the amount of preservative concentration.

Feb 3, 2025Z-2323-2025—open, classified

Multiple complaints indicating lower than expected quality control (QC) results and in some instances QC recovery below the lower limit of the package insert acceptance range when testing is performed with HemosIL Liquid Anti-Xa and HemosIL Heparin Calibrator. In some complaints, failure to pass QC resulted in patient testing delays.

Dec 18, 2024Z-1020-2025—open, classified

Control indicating lower than expected quality control (QC) results and in some instances QC recovery below the lower limit of the package insert acceptance range.

Sep 29, 2023Z-0359-2024—open, classified

Internal testing identified that the GEM Premier PAKs (cartridges) may exhibit an over-recovery (i.e., positive bias) of pO2 results in the low range (at pO2 levels less than 60 mmHg) that are outside of labeled performance specifications for pO2. The positive bias may lead to false positive for medical decision levels at pO2 < 60 mmHg, which may result in failure to detect and/or adequately treat hypoxemia and lead to a delay in treatment. The quality control procedures for the Non-iQM GEM Premier 3000 may not detect the non-conformance.

Sep 29, 2023Z-0358-2024—open, classified

Internal testing identified that the GEM Premier PAKs (cartridges) may exhibit an over-recovery (i.e., positive bias) of pO2 results in the low range (at pO2 levels less than 60 mmHg) that are outside of labeled performance specifications for pO2. The positive bias may lead to false positive for medical decision levels at pO2 < 60 mmHg, which may result in failure to detect and/or adequately treat hypoxemia and lead to a delay in treatment. The quality control procedures for the Non-iQM GEM Premier 3000 may not detect the non-conformance.

Sep 29, 2023Z-0357-2024—open, classified

Internal testing identified that the GEM Premier PAKs (cartridges) may exhibit an over-recovery (i.e., positive bias) of pO2 results in the low range (at pO2 levels less than 60 mmHg) that are outside of labeled performance specifications for pO2. The positive bias may lead to false positive for medical decision levels at pO2 < 60 mmHg, which may result in failure to detect and/or adequately treat hypoxemia and lead to a delay in treatment. The quality control procedures for the Non-iQM GEM Premier 3000 may not detect the non-conformance.

Jul 13, 2023Z-2578-2023—open, classified

Sample misidentification could occur under specific conditions and patient management altered based on an incorrectly assigned result

Feb 3, 2023Z-1305-2023—open, classified

Removes the test definition for HemosIL Liquid Anti-Xa (PN 0020302600 and 0020302601) from the ACL Elite/Elite Pro instruments

Feb 3, 2023Z-1304-2023—open, classified

Removes the test definition for HemosIL Liquid Anti-Xa (PN 0020302600 and 0020302601) from the ACL Elite/Elite Pro instruments

Feb 3, 2023Z-1306-2023—open, classified

Removes the test definition for HemosIL Liquid Anti-Xa (PN 0020302600 and 0020302601) from the ACL Elite/Elite Pro instruments

Feb 3, 2023Z-1307-2023—open, classified

Removes the test definition for HemosIL Liquid Anti-Xa (PN 0020302600 and 0020302601) from the ACL Elite/Elite Pro instruments

Apr 8, 2022Z-1052-2022—open, classified

Variable and out of specification QC results with HemosIL ReadiPlasTin. IL will remove all lots from the market and convert customers to an alternative prothrombin time (PT) reagent, specifically HemosIL RecombiPlasTin 2G.

Feb 22, 2022Z-1014-2022—open, classified

Updated and revised user instructions issued 7/14/22. Potential carryover issue may cause elevated quality control and sample results for heparin, apixaban or rivaroxaban when HemosIL Liquid Anti-Xa reagent is used in the same run with both HemosIL Liquid Antithrombin and HemosIL Q.F.A. Thrombin (Bovine), specific to instrument models that utilize a single reagent probe

Oct 13, 2021Z-0276-2022—open, classified

The firm has received customer reports of performance issues with the affected lot, including increased imprecision, out of range quality controls, and prolonged sample results. If quality controls are not performed or do not pass for each vial of reagent, there is a potential risk of reporting an erroneous result.

Aug 25, 2021Z-0149-2022—open, classified

Labeled On-board instrument stability issue for current and future lots, reduced On-board Instrument Stability from 7 days to 5 days

Aug 25, 2021Z-0150-2022—open, classified

Labeled On-board instrument stability issue for current and future lots, reduced On-board Instrument Stability from 7 days to 5 days

Aug 25, 2021Z-0151-2022—open, classified

Labeled On-board instrument stability issue for current and future lots, reduced On-board Instrument Stability from 7 days to 5 days

Jul 23, 2019Z-2485-2019—terminated

Prolonged clotting times

Jul 23, 2019Z-2486-2019—terminated

Prolonged clotting times

Jul 23, 2019Z-2487-2019—terminated

Prolonged clotting times

Aug 1, 2018Z-0077-2019—terminated

There is a potential for increased imprecision, out of range quality controls and prolonged sample results.

Aug 2, 2017Z-0895-2018—terminated

Instrumentation Laboratory Co. received customer reports of performance issues with some vials of Lot Nos. N1166235 and N0177760, including increased imprecision, out of range quality controls and prolonged sample results.

Dec 18, 2015Z-0736-2016—terminated

This Lot is not meeting labeled on-board instrument stability claims of 5 days.

Nov 21, 2014Z-0832-2015—terminated

Some vials of HemosIL PT-Fibrinogen HS PLUS, Part No. 0008469810 (various lots manufactured prior to June 2014) exhibit a yellow/brownish color after reconstitution (yellow color or darker) instead of the typical white to off-white color. Vials exhibiting this yellow/brownish color were observed to cause prolonged prothrombin (PT) clotting times.

Jun 3, 2014Z-2062-2014—terminated

Potential for sample misidentification.

Jun 3, 2014Z-2066-2014—terminated

Potential for sample misidentification.

Jun 3, 2014Z-2060-2014—terminated

Potential for sample misidentification.

Jun 3, 2014Z-2063-2014—terminated

Potential for sample misidentification.

Jun 3, 2014Z-2065-2014—terminated

Potential for sample misidentification.

Jun 3, 2014Z-2064-2014—terminated

Potential for sample misidentification.

Jun 3, 2014Z-2061-2014—terminated

Potential for sample misidentification.

Nov 15, 2013Z-0514-2014—terminated

HemosIL Low, Abnormal, Normal Controls UNASSAYED (no-value assigned) lacks 510(k) approval

Nov 15, 2013Z-0516-2014—terminated

HemosIL Low, Abnormal, Normal Controls UNASSAYED (no-value assigned) lacks 510(k) approval

Nov 15, 2013Z-0515-2014—terminated

HemosIL Low, Abnormal, Normal Controls UNASSAYED (no-value assigned) lacks 510(k) approval

Jul 19, 2013Z-2249-2013—terminated

Potential carryover issue that can can cause shortened APTT clotting times on the instrument.

Jul 19, 2013Z-2247-2013—terminated

Potential carryover issue that can can cause shortened APTT clotting times on the instrument.

Jul 19, 2013Z-2245-2013—terminated

Potential carryover issue that can can cause shortened APTT clotting times on the instrument.

Jul 19, 2013Z-2246-2013—terminated

Potential carryover issue that can can cause shortened APTT clotting times on the instrument.

Jul 19, 2013Z-2244-2013—terminated

Potential carryover issue that can can cause shortened APTT clotting times on the instrument.

Jul 19, 2013Z-2250-2013—terminated

Potential carryover issue that can can cause shortened APTT clotting times on the instrument.

Jul 19, 2013Z-2248-2013—terminated

Potential carryover issue that can can cause shortened APTT clotting times on the instrument.

Apr 9, 2013Z-1784-2013—terminated

Instrumentation Laboratory is recalling HemosIL RecombiPlasTin 2G (RPT2G), Part No. 0020009580 (8 mL Size) due to being Out of Specification.

Aug 3, 2012Z-2391-2012—terminated

Low Abnormal Fibrinogen Sample Reports as Normal and High Fibrinogen Sample Reports as Low

Aug 3, 2012Z-2392-2012—terminated

Low Abnormal Fibrinogen Sample Reports as Normal and High Fibrinogen Sample Reports as Low

Aug 3, 2012Z-2389-2012—terminated

Low Abnormal Fibrinogen Sample Reports as Normal and High Fibrinogen Sample Reports as Low

Aug 3, 2012Z-2390-2012—terminated

Low Abnormal Fibrinogen Sample Reports as Normal and High Fibrinogen Sample Reports as Low

Aug 3, 2012Z-2388-2012—terminated

Low Abnormal Fibrinogen Sample Reports as Normal and High Fibrinogen Sample Reports as Low

Aug 3, 2012Z-2387-2012—terminated

Low Abnormal Fibrinogen Sample Reports as Normal and High Fibrinogen Sample Reports as Low

Apr 11, 2012Z-1519-2012—terminated

Falsely elevated levels may be reported with the HemosIL von Willebrand Factor Activity assay.

May 31, 2011Z-2806-2011—terminated

K+ results on the GEM Premier 4000 are too low when compared to a reference analyzer, with biases exceeding allowable error claim of a 0.5 moUL

May 31, 2011Z-2805-2011—terminated

K+ results on the GEM Premier 4000 are too low when compared to a reference analyzer, with biases exceeding allowable error claim of a 0.5 moUL

May 31, 2011Z-2804-2011—terminated

K+ results on the GEM Premier 4000 are too low when compared to a reference analyzer, with biases exceeding allowable error claim of a 0.5 moUL

May 31, 2011Z-2803-2011—terminated

K+ results on the GEM Premier 4000 are too low when compared to a reference analyzer, with biases exceeding allowable error claim of a 0.5 moUL

May 11, 2011Z-2673-2011—terminated

Software upgrade: misuse of the barcode gun by repeatedly clicking can cause the instrument to attach test results to an incorrect patient ID.

Feb 14, 2011Z-2165-2011—terminated

Measurement (amperometric) spike can occur early in cartridge life on the glucose and lactate sensors during patient blood analysis, leading to erroneously high results

Nov 11, 2010Z-0803-2011—terminated

Sporadically lowered APTT results were observed with the PT/APTT Test Groups.

Nov 11, 2010Z-0807-2011—terminated

Sporadically lowered APTT results were observed with the PT/APTT Test Groups.

Nov 11, 2010Z-0804-2011—terminated

Sporadically lowered APTT results were observed with the PT/APTT Test Groups.

Nov 11, 2010Z-0805-2011—terminated

Sporadically lowered APTT results were observed with the PT/APTT Test Groups.

Nov 11, 2010Z-0806-2011—terminated

Sporadically lowered APTT results were observed with the PT/APTT Test Groups.

Aug 13, 2010Z-0136-2011—terminated

Software: New data check, "Multiple Threshold Check", was added to identify and fail abnormal (bimodal) clot curves

Aug 13, 2010Z-0135-2011—terminated

Software: New data check, "Multiple Threshold Check", was added to identify and fail abnormal (bimodal) clot curves

Aug 13, 2010Z-0137-2011—terminated

Software: New data check, "Multiple Threshold Check", was added to identify and fail abnormal (bimodal) clot curves

Aug 13, 2010Z-0138-2011—terminated

Software: New data check, "Multiple Threshold Check", was added to identify and fail abnormal (bimodal) clot curves

Jun 19, 2007Z-1127-2007—terminated

ACL TOP unit, when in emergency stop may release liquid during recovery sequence and contaminate sample tube.

Mar 27, 2007Z-0778-2007—terminated

Instrument in Micro Sampling Mode failed to aspirate and no error code was generated and an incorrect patient report could result

Mar 7, 2006Z-1246-06—terminated

Firm received 2 complaints concerning incorrect prothrombin time (PT) results while using the reagents on samples of patients taking the antibiotic CUBICIN (Daptomycin for injection).

Mar 7, 2006Z-1247-06—terminated

Firm received 2 complaints concerning incorrect prothrombin time (PT) results while using the reagents on samples of patients taking the antibiotic CUBICIN (Daptomycin for injection).

Dec 16, 2005Z-0378-06—terminated

Software error may report higher results for glucose and lactate

May 19, 2005Z-0915-05—terminated

Patient prothrombin time (PT) may report low for individuals on anticoaglant therapy

Mar 4, 2004Z-0736-04—terminated

Software may cause instrument to omit step causing reagent carrover which may effect patient test result

Mar 4, 2004Z-0737-04—terminated

Software may cause instrument to omit step causing reagent carrover which may effect patient test result

Aug 28, 2003Z-0027-04—terminated

Lactate Disposable Membrane Caps linearity was determined to be significantly biased and could potentially cause erroneous patient results above 6.0 mmol/L.

Mar 7, 2003Z-0845-03—terminated

Incorrect bar code applied to cartridges could result in inaccurate pO2 value

Mar 7, 2003Z-0846-03—terminated

Incorrect bar code applied to cartridges could result in inaccurate pO2 value